Form 4: Revolution Medicines Exec Sells Shares Under 10b5-1 Plan

Revolution Medicines' President of R&D, Stephen Michael Kelsey, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 trading plan.

Summary

• Stephen Michael Kelsey, President, Research and Development at Revolution Medicines, Inc. (RVMD), reported transactions under a Rule 10b5-1 trading plan adopted on February 28, 2025.
• On September 11, 2025, Kelsey exercised options to acquire 100,000 shares of common stock at an exercise price of $4.73 per share.
• Immediately following, on September 11, 2025, he sold a total of 100,000 shares of common stock in two separate transactions: 44,059 shares at a weighted average price of $43.5771 and 55,941 shares at a weighted average price of $44.4847.
• On September 15, 2025, Kelsey exercised options to acquire 25,000 shares of common stock at an exercise price of $4.73 per share.
• Immediately following, on September 15, 2025, he sold a total of 25,000 shares of common stock in two separate transactions: 23,682 shares at a weighted average price of $45.9175 and 1,318 shares at a weighted average price of $46.9302.
• Following these transactions, Kelsey beneficially owns 289,414 shares of common stock, which includes 94,426 restricted stock units.
• His derivative holdings decreased from 55,055 stock options to 30,055 stock options after the exercises.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions under a pre-arranged 10b5-1 plan, which is generally considered neutral in terms of market sentiment as it's not indicative of new, non-public information.

Positives

• The insider exercised options at a significantly lower price ($4.73) compared to the sale prices (ranging from $43.5771 to $46.9302), indicating a substantial profit for the reporting person.
• Transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests the sales were scheduled in advance and not based on immediate, non-public information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be interpreted by the market as a reduction in insider exposure, although this is mitigated by the pre-arranged nature of the plan.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• Stephen Michael Kelsey is identified as the President, Research and Development of Revolution Medicines, Inc.

Industry Context

This filing reports routine insider transactions under a pre-arranged trading plan, which is a common practice among executives in publicly traded companies across all industries, including biotechnology. It does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minor impact. Routine insider selling under a 10b5-1 plan is generally not seen as a strong signal of future performance, but it does represent a reduction in insider ownership.

Key Dates

Keywords

RVMD, Revolution Medicines, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Executive Compensation, Biotechnology